BeOne's Brukinsa plus rituximab cut disease progression risk by 43% versus chemoimmunotherapy in a Phase 3 frontline mantle cell lymphoma trial.
June 30, 2026 06:00 AM EDTUpdated 06:26 AM
R&DPharma
BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma study
Lei Lei Wu
News Reporter
A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new…
BeOne Medicines reported positive Phase 3 BRUKINSA data in mantle cell lymphoma, reducing progression or death risk by 43% ahead…
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), un'azienda oncologica globale, oggi ha annunciato i risultati…
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer,…
BeOne’s Brukinsa hits goal in mantle cell lymphoma confirmatory trial
BeOne Medicines Advances Chemotherapy-Free Lymphoma Strategy - BeOne Medicines (NASDAQ:ONC)
BeOne Medicines annuncia i risultati positivi di fase 3 per BRUKINSA, come trattamento di prima linea per il linfoma a cellule mantellari (MCL)
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
After monotherapy failure, AbbVie and Genmab tout Epkinly combo win in DLBCL
